These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 32031431)

  • 1. Companion and complementary diagnostics for infectious diseases.
    Dailey PJ; Elbeik T; Holodniy M
    Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein array-based companion diagnostics in precision medicine.
    Poulsen TBG; Karamehmedovic A; Aboo C; Jørgensen MM; Yu X; Fang X; Blackburn JM; Nielsen CH; Kragstrup TW; Stensballe A
    Expert Rev Mol Diagn; 2020 Dec; 20(12):1183-1198. PubMed ID: 33315478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of Rapid Molecular Infectious Disease Diagnostics: the Role of Diagnostic and Antimicrobial Stewardship.
    Messacar K; Parker SK; Todd JK; Dominguez SR
    J Clin Microbiol; 2017 Mar; 55(3):715-723. PubMed ID: 28031432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2014 Apr; 39(2):210-4. PubMed ID: 24405254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan.
    Shimazawa R; Ikeda M
    Expert Rev Mol Diagn; 2020 Jun; 20(6):601-610. PubMed ID: 32064968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intellectual property considerations for molecular diagnostic development with emphasis on companion diagnostics.
    Glorikian H; Warburg RJ; Moore K; Malinowski J
    Expert Opin Ther Pat; 2018 Feb; 28(2):123-128. PubMed ID: 29224409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists.
    Wenzler E; Maximos M; Asempa TE; Biehle L; Schuetz AN; Hirsch EB
    Pharmacotherapy; 2023 Apr; 43(4):264-278. PubMed ID: 36825480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Stewardship: Opportunity for a Laboratory-Infectious Diseases Partnership.
    Patel R; Fang FC
    Clin Infect Dis; 2018 Aug; 67(5):799-801. PubMed ID: 29547995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized health care beyond oncology: new indications for immunoassay-based companion diagnostics.
    Batrla R; Jordan BW
    Ann N Y Acad Sci; 2015 Jun; 1346(1):71-80. PubMed ID: 25866164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A better pathway to approval of 21st century cures?
    The Lancet Infectious Diseases
    Lancet Infect Dis; 2017 Feb; 17(2):117. PubMed ID: 28134099
    [No Abstract]   [Full Text] [Related]  

  • 12. Current and Future Opportunities for Rapid Diagnostics in Antimicrobial Stewardship.
    Timbrook TT; Spivak ES; Hanson KE
    Med Clin North Am; 2018 Sep; 102(5):899-911. PubMed ID: 30126579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
    Roscoe DM; Hu YF; Philip R
    Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of new antibiotics for the treatment of infections in the emergency department.
    Talan DA
    Ann Emerg Med; 1994 Sep; 24(3):473-89. PubMed ID: 8080145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in the clinical implementation of precision medicine companion diagnostics.
    Keeling P; Clark J; Finucane S
    Expert Rev Mol Diagn; 2020 Jun; 20(6):593-599. PubMed ID: 32336167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDx, NGS and regulation: five perspectives from the Pistoia Alliance.
    Wise J; Furness M; McWilliams S; Patton S
    Drug Discov Today; 2019 Nov; 24(11):2120-2125. PubMed ID: 31306783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of developmental approaches to companion animal antimicrobials: providing for the unmet therapeutic needs of dogs and cats.
    ; Apley M; Claxton R; Davis C; DeVeau I; Donecker J; Lucas A; Neal A; Papich M
    J Vet Pharmacol Ther; 2010 Apr; 33(2):196-201. PubMed ID: 20444045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.
    Rayner CR; Smith PF; Andes D; Andrews K; Derendorf H; Friberg LE; Hanna D; Lepak A; Mills E; Polasek TM; Roberts JA; Schuck V; Shelton MJ; Wesche D; Rowland-Yeo K
    Clin Pharmacol Ther; 2021 Apr; 109(4):867-891. PubMed ID: 33555032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects.
    Olsen D; Jørgensen JT
    Front Oncol; 2014; 4():105. PubMed ID: 24904822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Companion Diagnostic Labelling: Implementation of FDA's April 2020 Guidance for Industry for In Vitro CDx Labeling for Specific Oncology Therapeutic Groups.
    Cooper L; Chen J
    Ther Innov Regul Sci; 2022 Sep; 56(5):689-697. PubMed ID: 35689144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.